FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in ...

Retrieved on: 2021-05-28 01:41:15

Tags for this article:

Click the tags to see associated articles and topics

FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in .... View article details on hiswai:

Excerpt

The EMDAC based its recommendation on safety and efficacy data from the pivotal TN-10 Study in which a single 14-day course of teplizumab ...

Article found on: www.citizentribune.com